Device Trial Radar · NCT07300852
DSLT in Normal Tension Glaucoma (NTG) Asian Eyes
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jan 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Ngoc Nguyen Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alcon Research
- First posted
- Dec 24, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy of direct selective laser trabeculoplasty (DSLT) or laser treatment in Asian patients with normal tension glaucoma. The main question it aims to answer is: Does the DSLT reduce intraocular pressure (IOP) and medication use in Asian NTG subjects? Participants will attend routine follow-up visits with their eye surgeon and glaucoma testing such as optical coherence tomography (OCT) imaging and visual field test(s) after the laser study treatment.
Conditions
- Normal Tension Glaucoma (NTG)
- Glaucoma
- Open Angle Glaucoma (OAG)
- Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)Device
Direct Selective Laser Trabeculoplasty (DSLT) is a non-contact laser procedure that delivers energy to the trabecular meshwork without the need for a gonioscopy lens. The BELKIN Vision Eagle device automatically aligns and applies laser pulses to lower intraocular pressure in subjects with normal tension glaucoma. All participants receive a single DSLT treatment followed by routine post-procedure evaluations including IOP checks, visual field testing, and OCT imaging.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Intraocular Pressure (IOP)Time frame: 12 months post procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ngoc Nguyen M.D.
San Jose, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.